Regulation, Policy Shifts Reshape Crypto Market Landscape

SEC Ends Gemini Earn Case After Full Investor Repayment

The U.S. Securities and Exchange Commission has agreed to dismiss its enforcement case against Gemini Space Station, the cryptocurrency exchange founded by Tyler and Cameron Winklevoss, after customers in its Gemini Earn lending program were repaid in full. In a joint filing in federal court in Manhattan, the SEC and Gemini cited the 100% in‑kind return of approximately $940 million of crypto assets to Earn users through the Genesis Global Capital bankruptcy process between May and June 2024.

The SEC had charged Genesis Global Capital and Gemini Trust Company in 2023 with illegally selling securities to hundreds of thousands of investors via Gemini Earn, under which customers lent crypto to Genesis in exchange for interest. Genesis froze accounts in November 2022 but, unlike some peers from the 2022 market crash, ultimately returned crypto rather than liquidating assets and paying cash. The SEC said the full recovery and related settlements made dismissal appropriate, while stressing the move did not signal a broader shift in its position on other cases.

Gemini, which now trades on Nasdaq and is valued at about $1.14 billion according to LSEG data, did not immediately comment on the dismissal. The case’s resolution follows a broader change in Washington’s posture toward digital assets under President Donald Trump, who has pledged more favorable crypto rules and aims to promote mainstream use of digital currencies.

Stablecoin Rewards Fight Pits Crypto Industry Against Banks

In parallel with enforcement developments, U.S. lawmakers are advancing a market structure bill that includes a contentious ban on paying rewards on idle stablecoin balances, a provision that has split the industry. Galaxy Digital CEO Mike Novogratz told Anthony Scaramucci that crypto firms are “going to lose that battle” against what he called a “very strong” banking lobby, which supports limits on such rewards while banks can still pay interest on dollar deposits.

Novogratz said he expects a compromise in which stablecoin issuers may be allowed to offer usage‑based reward points but not yield on static balances. He described the overall bill as positive for the sector’s ability to move forward, suggesting the industry could accept constraints now and revisit them “in round two” in a few years. Fresh from meetings in Washington, he pointed to what he sees as strong commitment among Democrats, including Senate Minority Leader Chuck Schumer, to pass the legislation after concluding it was “really bad politics to be anti‑crypto.”

The rewards clause has already had consequences: Coinbase withdrew its support for the bill shortly before a vote, arguing that banning yield on stablecoin balances, while banks can pay interest, fails to provide the “level playing field” sought by CEO Brian Armstrong. Armstrong has advocated for customers’ ability to earn yields such as 3.8% on their stablecoins, making the rewards issue a focal point in the ongoing regulatory debate.

Circle’s Valuation Questioned After NYSE Listing and Pullback

Circle Internet Group, issuer of the USDC stablecoin and newly listed on the New York Stock Exchange under ticker CRCL, is drawing fresh scrutiny from fundamental analysts. A discounted cash flow analysis using a two‑stage free cash flow to equity model estimates Circle’s intrinsic value at about $62.02 per share, versus a recent market price around $71.33, implying the stock may be roughly 15% overvalued on that basis.

The model is based on latest 12‑month free cash flow of about $329.2 million and forecasts that include projected free cash flow of $434.7 million in 2026, $463.2 million in 2027 and $738.1 million in 2030, with extrapolations through 2035. On Simply Wall St’s six‑point valuation framework Circle scores 1 out of 6, with both the DCF and a price‑to‑sales comparison suggesting a premium. Circle currently trades at 6.96 times sales, above the broader software industry average of 4.54 times and above a modelled “Fair Ratio” of 4.61 times, though below a selected peer group at 8.25 times.

The scrutiny comes after a sharp pullback in Circle’s stock, with seven‑day, 30‑day and year‑to‑date returns of minus 9.3%, minus 13.7% and minus 14.5% respectively. At the same time, its role as a key USDC infrastructure provider and one of the few pure‑play stablecoin exposures in public markets has attracted attention, leaving investors weighing growth potential against valuation and sector‑specific risks.

Brand, Dividend and Funding Narratives in Broader Equity Market

Outside pure crypto, several companies connected to financial markets and risk assets are being reassessed through updated valuation lenses. Under Armour is investigating a major data breach affecting about 72 million customer records while simultaneously implementing senior leadership changes and a unified operating model for product, brand and marketplace. Commentary frames the breach as a test of customer trust and brand resilience at a time when earnings remain thin and cyber and governance risks are rising, even as the share price has shown near‑term strength.

In income‑oriented equities, Acuity Inc. has raised its quarterly dividend by 17% to $0.20 per share, payable February 13, 2026, a move positioned as reinforcing its image as a steady, cash‑generative industrial technology business in lighting, controls and building management. Analysis notes that while the higher payout fits a pattern of incremental raises and buybacks, it also sharpens focus on issues such as relatively low forecast return on equity, insider selling and a board that has not refreshed in several years.

Among smaller, higher‑risk names, Tenaya Therapeutics has completed a $60 million capital raise that extends its cash runway into mid‑2027. Despite this, the clinical‑stage gene therapy company’s shares have dropped 56% over 90 days and nearly 40% over a year. With the stock around $0.73 and trading at 1.9 times book value versus a 2.7 times average for U.S. biotech peers, it screens as cheaper than many comparables. Commentators suggest that while the lower price‑to‑book multiple could signal market caution about its balance sheet and pipeline, it may also reflect clinical and loss‑making risks that could quickly reset its valuation.